/
DCF Valuation
Base-case fair value
$66.67
Intrinsic $88.89 · 25% MOS
Current price: $91.09
Base-case summary
Our base-case DCF for Iradimed Corp (IRMD) projects 10 years of free cash flow growth at 17.8% for years 1–5 and 8.9% for years 6–10, anchored to 17.8% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $24M in trailing free cash flow, this produces an intrinsic value of $88.89 per share. A 25% safety margin gives a fair value of $66.67, suggesting the stock is currently 27% overvalued against the $91.09 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$24M
Cash & equivalents
$56M
Total debt
$0
Shares outstanding
13M